Cargando…

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials

BACKGROUND: In a Phase 3 trial, the Janssen COVID-19 vaccine, Ad26.COV2.S, showed robust efficacy against severe–critical COVID-19 in countries where different SARS-CoV-2 variants were circulating. We evaluated Ad26.COV2.S-elicited antibody neutralizing activity against variants of concern (VOC) B.1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Gars, Mathieu, Sadoff, Jerald, Jongeneelen, Mandy, Heerwegh, Dirk, Shukarev, Georgi, Truyers, Carla, de Groot, Anne Marit, Scheper, Gert, Hendriks, Jenny, Brandenburg, Boerries, Struyf, Frank, Van Hoof, Johan, Douoguih, Macaya, Schuitemaker, Hanneke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Late Breaker Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644272/ http://dx.doi.org/10.1093/ofid/ofab466.1638

Ejemplares similares

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
por: Sadoff, Jerald, et al.
Publicado: (2021)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
por: Sadoff, Jerald, et al.
Publicado: (2022)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
por: Sadoff, Jerald, et al.
Publicado: (2021)

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
por: Alter, Galit, et al.
Publicado: (2021)

LB10. Impact of SARS-CoV-2 Delta Variant on the Spectrum of Pediatric COVID-19 Disease in Arkansas
por: Romero, Jose R, et al.
Publicado: (2021)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia
por: Cassino, Cara, et al.
Publicado: (2021)

LB9. Longitudinal antibody dynamics in children infected with SARS-CoV-2 through 6 months post-infection
por: Gentles, Lauren E, et al.
Publicado: (2021)

LB-10. Rapid Assessments of Non-Pharmaceutical Intervention Uptake and Population Mobility Patterns Elucidate SARS-Cov-2 Transmission Dynamics
por: Wesolowski, Amy, et al.
Publicado: (2020)

LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
por: Evering, Teresa H, et al.
Publicado: (2021)

Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
por: Ong-Lim, Anna Lisa, et al.
Publicado: (2022)

LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial
por: Brown, Elizabeth R, et al.
Publicado: (2020)

LB-19. Association between contract staffing and reported outbreaks of SARS-CoV-2 in a cluster-randomized trial of 965 U.S. nursing homes
por: McConeghy, Kevin, et al.
Publicado: (2020)

LB-15. A Trans-Governmental Collaborative Effort to Independently Evaluate SARS-CoV-2 Serology Assays Using Well-Characterized Sample Panels
por: Shawar, Ribhi, et al.
Publicado: (2020)

LB-18. Broad and Prevalent SARS-CoV-2 CD8+ T Cell Response in Recovered COVID-19 Individuals Demonstrates Kinetics of Early Differentiation
por: Kared, Hassen, et al.
Publicado: (2020)

LB8. Lower SARS-CoV-2 IgG and Pseudovirus Neutralization Titers Post-mRNA Vaccination among People Living with HIV
por: Spinelli, Matthew A, et al.
Publicado: (2021)

LB-16. Association Between Universal Face Shield in a Quaternary Care Center and Reduction of SARS-COV2 Infections Among Healthcare Personnel and Hospitalized Patients
por: Hemmige, Vagesh, et al.
Publicado: (2020)

LB-12. SARS-CoV-2 RNA and Antibodies among People Experiencing Homelessness and Staying in Shelters or Outdoor Encampments in Denver, Colorado, May-July 2020
por: McCormick, David, et al.
Publicado: (2020)

LB-9. Development of a SARS-CoV2 vaccine, ChAdOx1 nCoV19: immunogenicity and safety in older adults
Publicado: (2020)

LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)
por: Ducher, Annie, et al.
Publicado: (2020)

LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
por: Levin, Myron J, et al.
Publicado: (2021)

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009)

LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials
por: D'Amico, Ronald, et al.
Publicado: (2020)

Quantifying Antibody Persistence After a Single Dose of COVID‐19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation Approach
por: Dari, Anna, et al.
Publicado: (2022)

The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review
por: Muszbek, N, et al.
Publicado: (2008)

Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy
por: Gorkin, L, et al.
Publicado: (2006)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

T-01: Taux élevé d’infections respiratoires virales chez les patients hospitalisés et le personnel soignant, hiver 2014
por: Conort, G., et al.
Publicado: (2014)

LB-2. Relative Effectiveness of aIIV3 versus IIV4 and HD-IIV3 In Preventing Influenza-Related Medical Encounters in Adults ≥65 Years of Age at High Risk for Influenza Complications During the U.S. 2017–2018 and 2018–2019 Influenza Seasons
por: Fischer, Lauren, et al.
Publicado: (2020)

Sepsis Among Medicare Beneficiaries: 2. The Trajectories of Sepsis, 2012–2018*
por: Buchman, Timothy G., et al.
Publicado: (2020)

LB4. Casirivimab and Imdevimab for Treatment of Hospitalized Patients With COVID-19 Receiving Low Flow or No Supplemental Oxygen
por: Mylonakis, Eleftherios, et al.
Publicado: (2021)

LB18. Healthcare Utilization for Acute Respiratory Illness by Race/Ethnicity across Ambulatory, Emergency, and Hospital Settings
por: Mellis, Alexandra M, et al.
Publicado: (2021)

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

LB17. Immunosequencing of the T-Cell Receptor Repertoire Reveals Signatures Specific for Diagnosis and Characterization of Early Lyme Disease
por: Dalai, Sudeb C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hq5rol3h72gvhr4kj3t2afbc6p